Liraglutide in Preventing Delirium in Diabetic Elderly After Cardiac Surgery
Perioperative Application of Liraglutide for the Prevention of Postoperative Delirium Among Elderly Patients with Type 2 Diabetes Undergoing Cardiac Surgery: a Single-Center Randomized Controlled Study
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
260 participants
Nov 19, 2024
INTERVENTIONAL
Conditions
Summary
This study aims to clarify the preventive effect of perioperative liraglutide application on postoperative delirium in elderly patients with Type 2 diabetes undergoing cardiac surgery.
Eligibility
Inclusion Criteria3
- Age ≥ 60 years
- Type 2 diabetes
- Patients undergoing elective cardiac surgery
Exclusion Criteria14
- History of neurological or psychiatric disorders, such as schizophrenia, epilepsy, Parkinson's disease, severe dementia, etc
- Patients with communication difficulties, such as severe visual, auditory, or speech impairments
- History of central nervous system damage or surgery
- Cardiac function NYHA Class IV
- Severe liver dysfunction (Child-Pugh Class C)
- Severe renal failure requiring renal replacement therapy
- History of pancreatitis
- Type 1 diabetes
- Patients whose blood sugar is difficult to control within 4-8 mmol/L during the screening period
- Patients with medullary thyroid carcinoma or a family history of it
- Pregnant or breastfeeding women
- Intolerance or allergy to liraglutide
- Previous use of GLP-1A and SGLT2i
- Patients who refuse to sign the informed consent
Interventions
Subcutaneous injection of liraglutide: 0.6 mg administered the day before surgery, 1.8 mg administered post-anesthesia induction on the day of surgery, followed by 0.6 mg daily for the first three postoperative days.
Subcutaneous injection of Placebo: the same volume as liraglutide administrated at the corresponding times.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06361238